Dynavax Technologies (DVAX) said Thursday that topline data from part 1 of its phase 1/2 study of it
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
Dynavax Says Shingles Vaccine Candidate Achieves Immune Response 'Similar' to Shingrix
Published 2 months ago
Aug 21, 2025 at 1:01 PM
Positive
Auto